Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brieva

Showing results (311-320 of 376) with videos related to

Pageof 38
Sort By:
Veterinary Microbiology|October 2, 2018
Risk factors associated with hepatitis E virus in pigs from different production systemsPedro Lopez-Lopez, Maria de Los Angeles Risalde, Mario Frias, et al.
Scientific Reports|November 8, 2023
Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot studyCristina González Mingot, Sonia Santos Lasaosa, Laura Colàs Campàs, et al.
CNS Neuroscience & Therapeutics|April 16, 2018
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patientsBibiana Quirant-Sánchez, José V Hervás-García, Aina Teniente-Serra, et al.
Mediators of Inflammation|July 27, 2019
Th1Th17<sub>CM</sub> Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod TreatmentBibiana Quirant-Sánchez, Silvia Presas-Rodriguez, María José Mansilla, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2023
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS studyBruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, et al.
Journal of Clinical Medicine|June 13, 2025
Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six MonthsAgustín Sancho-Saldaña, Anna Gil-Sánchez, Bibiana Quirant-Sánchez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 23, 2013
A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MSC Ramo-Tello, L Grau-López, M Tintoré, et al.
Frontiers in Neuroscience|September 26, 2019
Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis PatientsHugo Gonzalo, Lara Nogueras, Anna Gil-Sánchez, et al.
Journal of Cosmetic Dermatology|May 6, 2026
International Expert Consensus on Integrated Skincare Active Ingredients for Pretreatment and Posttreatment Use With Medical Aesthetic Procedures to Enhance Skin BenefitsPeter Bjerring, Zoe D Draelos, Sabrina G Fabi, et al.
Journal of Personalized Medicine|December 24, 2021
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for NatalizumabJúlia Granell-Geli, Cristina Izquierdo-Gracia, Ares Sellés-Rius, et al.
Pageof 38

Showing results (311-320 of 376) with videos related to

Sort By:
Pageof 38
Veterinary Microbiology|October 2, 2018
Risk factors associated with hepatitis E virus in pigs from different production systemsPedro Lopez-Lopez, Maria de Los Angeles Risalde, Mario Frias, et al.
Scientific Reports|November 8, 2023
Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot studyCristina González Mingot, Sonia Santos Lasaosa, Laura Colàs Campàs, et al.
CNS Neuroscience & Therapeutics|April 16, 2018
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patientsBibiana Quirant-Sánchez, José V Hervás-García, Aina Teniente-Serra, et al.
Mediators of Inflammation|July 27, 2019
Th1Th17<sub>CM</sub> Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod TreatmentBibiana Quirant-Sánchez, Silvia Presas-Rodriguez, María José Mansilla, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2023
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS studyBruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, et al.
Journal of Clinical Medicine|June 13, 2025
Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six MonthsAgustín Sancho-Saldaña, Anna Gil-Sánchez, Bibiana Quirant-Sánchez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 23, 2013
A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MSC Ramo-Tello, L Grau-López, M Tintoré, et al.
Frontiers in Neuroscience|September 26, 2019
Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis PatientsHugo Gonzalo, Lara Nogueras, Anna Gil-Sánchez, et al.
Journal of Cosmetic Dermatology|May 6, 2026
International Expert Consensus on Integrated Skincare Active Ingredients for Pretreatment and Posttreatment Use With Medical Aesthetic Procedures to Enhance Skin BenefitsPeter Bjerring, Zoe D Draelos, Sabrina G Fabi, et al.
Journal of Personalized Medicine|December 24, 2021
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for NatalizumabJúlia Granell-Geli, Cristina Izquierdo-Gracia, Ares Sellés-Rius, et al.
Pageof 38